435 related articles for article (PubMed ID: 12567306)
1. Quinupristin-dalfopristin and linezolid: evidence and opinion.
Eliopoulos GM
Clin Infect Dis; 2003 Feb; 36(4):473-81. PubMed ID: 12567306
[TBL] [Abstract][Full Text] [Related]
2. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.
Raad I; Hachem R; Hanna H; Afif C; Escalante C; Kantarjian H; Rolston K
J Antimicrob Chemother; 2004 Apr; 53(4):646-9. PubMed ID: 14998986
[TBL] [Abstract][Full Text] [Related]
3. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS
Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781
[TBL] [Abstract][Full Text] [Related]
4. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia.
Erlandson KM; Sun J; Iwen PC; Rupp ME
Clin Infect Dis; 2008 Jan; 46(1):30-6. PubMed ID: 18171210
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin).
McNeil SA; Clark NM; Chandrasekar PH; Kauffman CA
Clin Infect Dis; 2000 Feb; 30(2):403-4. PubMed ID: 10671355
[No Abstract] [Full Text] [Related]
6. Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium.
Winston DJ; Emmanouilides C; Kroeber A; Hindler J; Bruckner DA; Territo MC; Busuttil RW
Clin Infect Dis; 2000 May; 30(5):790-7. PubMed ID: 10817685
[TBL] [Abstract][Full Text] [Related]
7. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
9. Linezolid and quinupristin/dalfopristin: novel antibiotics for gram-positive infections of the skin.
Schweiger ES; Scheinfeld NS; Tischler HR; Weinberg JM
J Drugs Dermatol; 2003 Aug; 2(4):378-83. PubMed ID: 12884459
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
Tünger A; Aydemir S; Uluer S; Cilli F
Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid.
Babcock HM; Ritchie DJ; Christiansen E; Starlin R; Little R; Stanley S
Clin Infect Dis; 2001 May; 32(9):1373-5. PubMed ID: 11303275
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin-resistant Enterococcus faecium osteomyelitis: successful treatment with quinupristin-dalfopristin.
Summers M; Misenhimer GR; Antony SJ
South Med J; 2001 Mar; 94(3):353-5. PubMed ID: 11284529
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin.
Noskin GA; Siddiqui F; Stosor V; Kruzynski J; Peterson LR
Clin Infect Dis; 1999 Mar; 28(3):689-90. PubMed ID: 10194104
[No Abstract] [Full Text] [Related]
14. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin.
Linden PK; Moellering RC; Wood CA; Rehm SJ; Flaherty J; Bompart F; Talbot GH;
Clin Infect Dis; 2001 Dec; 33(11):1816-23. PubMed ID: 11668430
[TBL] [Abstract][Full Text] [Related]
15. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
[TBL] [Abstract][Full Text] [Related]
16. Treatment of vancomycin-resistant enterococcus with quinupristin/dalfopristin and high-dose ampicillin.
Bethea JA; Walko CM; Targos PA
Ann Pharmacother; 2004 Jun; 38(6):989-91. PubMed ID: 15100393
[TBL] [Abstract][Full Text] [Related]
17. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report.
Swoboda S; Fritz S; Martignoni ME; Feldhues RA; Hoppe-Tichy T; Buchler MW; Geiss HK
J Antimicrob Chemother; 2005 Oct; 56(4):787-9. PubMed ID: 16143710
[TBL] [Abstract][Full Text] [Related]
18. Case of vancomycin-resistant Enterococcus faecium infection associated with a transjugular intrahepatic portosystemic shunt that was treated with quinupristin/dalfopristin after bacteremia persisted with alatrofloxacin therapy.
Zaman MM; Recco R; Tejwani U; Scuto TJ; Ahmed S; Hypolite A; Jayaraman G
Clin Infect Dis; 1999 Oct; 29(4):954-5. PubMed ID: 10589932
[No Abstract] [Full Text] [Related]
19. Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium.
Till M; Wixson RL; Pertel PE
Clin Infect Dis; 2002 May; 34(10):1412-4. PubMed ID: 11981739
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium.
Abb J
Int J Antimicrob Agents; 2007 Mar; 29(3):358-60. PubMed ID: 17229553
[No Abstract] [Full Text] [Related]
[Next] [New Search]
